Recent Press Releases

Global Biosimilars Market Value Could Hit $55 Billion by 2020, says GBI Research

NEW YORK (GBI Research), 30 June 2015 The global biosimilars market value is expected to reach $20 billion by the end of 2015 and could hit $55 billion by 2020, with growth primarily driven by a...

Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma

INDIANAPOLIS and OXFORD, England, June 29, 2015 /PRNewswire/ -- Eli Lil

AbbVie to Expand its Medical Device Operation in Sligo

Creation of 50 new jobs and investment of €40 million over 4 years Sligo 29th June 2015 –Minister for Jobs, Enterprise and Innovation Richard Bruton TD, today announced that AbbVie (ABBV:...

Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Union

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU

First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU Farydak shown to slow progression of rare blood cancer The European Medicines Agency (EMA) has recommended...

EYLEA® (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion

TARRYTOWN, N.Y., June 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval...

BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping SAN RAFAEL, Calif., June 25, 2015 (GLOBE NEWSWIRE) -- BioMarin...

UK Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit

INDIANAPOLIS, June 25, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the C

Veracyte Announces National Network Agreement with Aetna

SOUTH SAN FRANCISCO, Calif., June 25, 2015 /PRNewswire/ -- 

Diabetes Scholars Foundation Announces 2015 Scholarship Recipients

Lilly Diabetes donation helps 21 students attend college through Tomorrow's Leaders Scholarships

ROLLING MEADOWS, Ill. and

Class Action Alleges Novartis Gleevec Patent Infringement Suit a Sham

Complaint seeks permanent injunctive relief to prevent overcharges and damages, and bring generic Gleevec to market BOSTON – A class-action lawsuit filed against Novartis alleges that the...

Novartis statement on Gleevec patent lawsuit

"We believe these claims are unsubstantiated. The patents covering Gleevec remain legally in force and are covered by a statutory presumption of validity. The patents are clearly directed to...

FDA Drug Safety Communication: FDA reporting permanent skin color changes associated with use of Daytrana patch (methylphenidate transdermal system) for treating ADHD

The U.S. Food and Drug Administration (FDA) is warning that permanent loss of skin color may occur with use of the Daytrana patch (methylphenidate transdermal system) for Attention Deficit...

CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA® for Adolescents and Young Adults 16 through 23 Years of Age

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to...

U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines

- GSK's BEXSERO® included in Category B recommendation by the Advisory Committee on Immunization Practices (ACIP)

PHILADELPHIA,

Reimbursement Uncertainties Trouble Life Sciences Companies – BDO Report

June 2015 Amanda Chun Bliss Integrated Communication (212) 584-5482 amanda@blissintegrated.com CHICAGO – June 15, 2015 – For many years, the success of life sciences companies relied...

FDA approves new antiplatelet drug used during heart procedure

FDA approves new antiplatelet drug used during heart procedure June 22, 2015 The U.S. Food and Drug Administration today approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents...

The Medicines Company Announces FDA Approval of KENGREAL (cangrelor) as an Adjunct to Percutaneous Coronary Intervention (PCI) for Reducing Thrombotic Events

The Medicines Company Announces FDA Approval of KENGREAL (cangrelor) as an Adjunct to Percutaneous Coronary Intervention (PCI) for Reducing Thrombotic Events Novel intravenous antiplatelet agent adds...

Eisai Announces FDA Approval of FYCOMPA® (perampanel) CIII for Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures in Patients with Epilepsy Age 12 and Older

WOODCLIFF LAKE, N.J., June 22, 2015 /PRNewswire/ -- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII for adjunctive therapy in...

Celimmune to Present Experimental Anti-IL-15 Antibody AMG 714 at 16th International Coeliac Disease Symposium

Oral Presentation to Highlight Rationale for the Study of AMG 714 in the Treatment of Celiac and Refractory Celiac Disease

LEBANON, N.J.<